ESRC Centre for Economic and Social Aspects of Genomics (Cesagen), Lancaster University, Lancaster, United Kingdom ; Institute of Advanced Studies, United Nations University, Yokohama, Japan.
PLoS One. 2013 Nov 12;8(11):e78737. doi: 10.1371/journal.pone.0078737. eCollection 2013.
Biological diversity in the patent system is an enduring focus of controversy but empirical analysis of the presence of biodiversity in the patent system has been limited. To address this problem we text mined 11 million patent documents for 6 million Latin species names from the Global Names Index (GNI) established by the Global Biodiversity Information Facility (GBIF) and Encyclopedia of Life (EOL). We identified 76,274 full Latin species names from 23,882 genera in 767,955 patent documents. 25,595 species appeared in the claims section of 136,880 patent documents. This reveals that human innovative activity involving biodiversity in the patent system focuses on approximately 4% of taxonomically described species and between 0.8-1% of predicted global species. In this article we identify the major features of the patent landscape for biological diversity by focusing on key areas including pharmaceuticals, neglected diseases, traditional medicines, genetic engineering, foods, biocides, marine genetic resources and Antarctica. We conclude that the narrow focus of human innovative activity and ownership of genetic resources is unlikely to be in the long term interest of humanity. We argue that a broader spectrum of biodiversity needs to be opened up to research and development based on the principles of equitable benefit-sharing, respect for the objectives of the Convention on Biological Diversity, human rights and ethics. Finally, we argue that alternative models of innovation, such as open source and commons models, are required to open up biodiversity for research that addresses actual and neglected areas of human need. The research aims to inform the implementation of the 2010 Nagoya Protocol on Access to Genetic Resources and the Equitable Sharing of Benefits Arising from their Utilization and international debates directed to the governance of genetic resources. Our research also aims to inform debates under the Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore at the World Intellectual Property Organization.
专利制度中的生物多样性一直是争议的焦点,但对专利制度中生物多样性存在情况的实证分析却很有限。为了解决这个问题,我们从全球生物多样性信息设施(GBIF)和生命百科全书(EOL)建立的全球名称索引(GNI)中对 1100 万份专利文献进行了文本挖掘,共涉及 600 万个拉丁物种名称。我们从 767955 份专利文献中的 23882 个属中确定了 76274 个完整的拉丁物种名称。25595 个物种出现在 136880 份专利文献的权利要求部分。这表明,涉及专利制度中生物多样性的人类创新活动主要集中在约 4%的分类学描述物种和 0.8-1%的预测全球物种上。在本文中,我们通过关注制药、被忽视的疾病、传统医学、基因工程、食品、杀生剂、海洋遗传资源和南极洲等关键领域,确定了生物多样性专利领域的主要特征。我们得出的结论是,人类创新活动和遗传资源的所有权的狭窄焦点不太可能长期符合人类的利益。我们认为,需要根据公平利益共享、尊重生物多样性公约目标、人权和道德原则,开放更广泛的生物多样性供研究和开发使用。最后,我们认为需要采用开源和公有领域等创新模式,开放生物多样性,以满足人类实际和被忽视的需求领域的研究。这项研究旨在为实施 2010 年《名古屋议定书》关于获取遗传资源和公平分享其利用所产生惠益以及针对遗传资源的国际治理的国际辩论提供信息。我们的研究还旨在为世界知识产权组织知识产权与遗传资源、传统知识和民间文学艺术政府间委员会的辩论提供信息。